Utilization of chromatin remodeling agents for lung cancer therapy.
Lung cancer is a disease with enormous global medical and economic impact that remains refractory to conventional treatment modalities. Recent insights regarding mechanisms pertaining to epigenetic regulation of gene expression during malignant transformation, together with the identification of agents that modulate chromatin structure provide new opportunities for the treatment and prevention of this lethal disease.
Schrump
David S
DS
Thoracic Oncology Section, Surgery Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892-1201, USA. david_schrump@nih.gov
Hong
Julie A
JA
Nguyen
Dao M
DM
D000818:Animals; D001374:Azacitidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D042002:Chromatin Assembly and Disassembly / Q000187:drug effects*; D019175:DNA Methylation / Q000187:drug effects; D015254:DNA Modification Methylases / Q000037:antagonists & inhibitors / Q000378:metabolism; D000077209:Decitabine; D047630:Depsipeptides / Q000627:therapeutic use; D044127:Epigenesis, Genetic / Q000187:drug effects; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism
D047630:Depsipeptides; D000077209:Decitabine; C087123:romidepsin; D015254:DNA Modification Methylases; D001374:Azacitidine